ustekinumab stelara - Search News

J&J suing Samsung Bioepis over Stelara biosimilar

Hosted on MSN · 10h

J&J suing Samsung Bioepis over Stelara biosimilar (update)

Johnson & Johnson (NYSE:JNJ) is suing Samsung Bioepis for breach of contract related to the launch of a biosimilar of J&J's blockbuster drug Stelara, also known as ustekinumab. According to a suit filed late Monday,

YAHOO!Finance · 5h

J&J sues Samsung Bioepis over ‘surreptitious’ breach of Stelara biosimilar contract

Samsung Bioepis has allegedly sub-licensed its Stelara biosimilar rights to a health conglomerate, breaching a previous settlement.

Business Standard · 1d

Biocon Biologics launches biosimilar alternative to Stelara in the US

YESINTEK is approved for Crohn's disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis, offering a cost-effective treatment for chronic autoimmune diseases

MarketWatch · 2d

Samsung Bioepis Announces US Launch of PYZCHIVA(R) (ustekinumab-ttwe), Biosimilar to Stelara

Samsung Bioepis Co., Ltd. today announced that PYZCHIVA(R) (ustekinumab-ttwe), a biosimilar to Stelara (ustekinumab), is now available in the United States. PYZCHIVA has been appr

Seeking Alpha on MSN · 1d

Sandoz launches biosimilar Pyzchiva in U.S. for all approved Stelara indications

Monday said that Pyzchiva (ustekinumab-ttwe) is now commercially available to patients across the U.S. Developed by Samsung Bioepis Co., and commercialized by Sandoz, Pyzchiva has been approved by the U.

centerforbiosimilars14h

3 Ustekinumab Biosimilars Launch on US Market

Three ustekinumab biosimilars enter the US market, expanding access to more affordable options referencing Stelara ...

Biocon Biologics unveils Yesintek biosimilar to Stelara in US

YESINTEK is a monoclonal antibody that disrupts IL-12 and IL-23 mediated signaling associated immune mediated diseases.

Medpage Today on MSN13d

Studies Point to Several Options for Ulcerative Colitis After Anti-TNF Failure

SAN FRANCISCO -- Research presented at the annual Crohn's and Colitis Congress included studies comparing the effectiveness ...

12hon MSN

Biocon share price in focus after arm launches product in US for autoimmune diseases

Biocon share price rose by 2.5% after its arm launched Yesintek, a biosimilar for autoimmune disorders in the US. Approved ...

4d

Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.

In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™for all indicationsmatching the reference product ...

1d

Biocon share price up 2% as arm launches Yesintek in US; check details here

Biocon share rose after Biocon Biologics, a subsidiary of Biocon, announced that Yesintek (ustekinumab-kfce) is now available ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results